The immune cells identified in an earlier work, which are known as M1 or classically activated macrophages, cause inflammation and possess a specific molecule, peroxisome proliferator-activated receptor-gamma, that, when activated, favors a switch to a type of macrophage that reduces the impact of inflammation. The activation of the receptor protein and the anti-inflammatory M2 macrophage switch plays a beneficial role in reducing the severity of the disease in the gut during experimentally induced inflammatory bowel disease.
Read the news release about the VA Tech study results on IBD.
Read other coverage about IBD:
– Risk of Death Heightened for IBD Patients With Healthcare-Associated Infections
– ACG Releases Podcasts Focused on IBD Treatment
– American College of Gastroenterology Supports IBD Awareness Efforts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.